guys...assuming positive trials and FDA approval...if RAP only manages to test 10% of the 151M cases of pneumonia in the developing world at $1/test we will have $15M in revenue next year. Subtract tax, 10%G&A and R&D costs and the ?2% UQ royalty and we'll have around $9.5M in earnings. At a PE of 30x the share price would be $0.42 . We're not even there yet.
Big News, page-17
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)